Meeting
2020 ASCO Virtual Scientific Program
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
Authors
Joao Victor Machado Alessi
Hospital Sírio-Libanês, São Paulo, Brazil
Joao Victor Machado Alessi , Biagio Ricciuti , Elizabeth Jimenez Aguilar , Fangxin Hong , Zihan Wei , Mizuki Nishino , Andrew J. Plodkowski , Peter Sawan , Jia Luo , Hira Rizvi , Brett W. Carter , John Heymach , Mehmet Altan , Matthew David Hellmann , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9568)
DOI
10.1200/JCO.2020.38.15_suppl.9568
Abstract #
9568
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2019 ASCO Annual Meeting
Mutational landscapes and PD-L1 expression in non-small cell lung cancer.
First Author: Kang Zhang